Cargando…

Pathogenesis of rheumatoid arthritis: how early is early?

Studies of cytokine expression in rheumatoid arthritis have provided key insights into the pathogenesis of disease and have offered clues for effective therapy. Patterns of T-cell products in chronic rheumatoid synovitis suggest that T helper type 1 cells contribute to the perpetuation of disease. H...

Descripción completa

Detalles Bibliográficos
Autor principal: Firestein, Gary S
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2005
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1175047/
https://www.ncbi.nlm.nih.gov/pubmed/15987499
http://dx.doi.org/10.1186/ar1780
_version_ 1782124498593513472
author Firestein, Gary S
author_facet Firestein, Gary S
author_sort Firestein, Gary S
collection PubMed
description Studies of cytokine expression in rheumatoid arthritis have provided key insights into the pathogenesis of disease and have offered clues for effective therapy. Patterns of T-cell products in chronic rheumatoid synovitis suggest that T helper type 1 cells contribute to the perpetuation of disease. However, there is no guarantee that the mechanisms of late disease are identical to very early rheumatoid arthritis. Evaluation of the cytokine profile at the earliest time points after onset of symptoms could identify novel targets that prevent progression to chronic arthritis.
format Text
id pubmed-1175047
institution National Center for Biotechnology Information
language English
publishDate 2005
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-11750472005-07-14 Pathogenesis of rheumatoid arthritis: how early is early? Firestein, Gary S Arthritis Res Ther Commentary Studies of cytokine expression in rheumatoid arthritis have provided key insights into the pathogenesis of disease and have offered clues for effective therapy. Patterns of T-cell products in chronic rheumatoid synovitis suggest that T helper type 1 cells contribute to the perpetuation of disease. However, there is no guarantee that the mechanisms of late disease are identical to very early rheumatoid arthritis. Evaluation of the cytokine profile at the earliest time points after onset of symptoms could identify novel targets that prevent progression to chronic arthritis. BioMed Central 2005 2005-06-17 /pmc/articles/PMC1175047/ /pubmed/15987499 http://dx.doi.org/10.1186/ar1780 Text en Copyright © 2005 BioMed Central Ltd
spellingShingle Commentary
Firestein, Gary S
Pathogenesis of rheumatoid arthritis: how early is early?
title Pathogenesis of rheumatoid arthritis: how early is early?
title_full Pathogenesis of rheumatoid arthritis: how early is early?
title_fullStr Pathogenesis of rheumatoid arthritis: how early is early?
title_full_unstemmed Pathogenesis of rheumatoid arthritis: how early is early?
title_short Pathogenesis of rheumatoid arthritis: how early is early?
title_sort pathogenesis of rheumatoid arthritis: how early is early?
topic Commentary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1175047/
https://www.ncbi.nlm.nih.gov/pubmed/15987499
http://dx.doi.org/10.1186/ar1780
work_keys_str_mv AT firesteingarys pathogenesisofrheumatoidarthritishowearlyisearly